Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
Cert. of designation
Quarterly results
Acq. announced
|
|
HARROW HEALTH, INC. (IMMY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ...|
Docs:
|
"AMENDED AND RESTATED BYLAWS OF HARROW, INC. dated as of September 29, 2023",
"Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. NASHVILLE, Tenn., September 29, 2023 – Harrow , a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company’ s current five-year strategic plan, which includes an exclusive focus on eyecare pharmaceuticals. “Given the growing recognition of the Harrow name within the ophthalmic community, along with the connection of the Harrow brand to what is now one of the largest portfolios of ophthalmic pharmaceutical products in the U.S. market, we believed it was the right time to represent our exclusive commitment to the ophthalmic market by shortening our corporate name to Harrow, Inc.,” said Mark L. Baum, Chief Execu..." |
|
| 08/09/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/18/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results |
| 01/23/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits Interact...|
Docs:
|
"Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE and Will Begin Receiving Net Profit Payments for Acquired Products",
"UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET The accompanying unaudited pro forma condensed consolidated balance sheet for Harrow Health, Inc. and subsidiaries as of September 30, 2022 gives effect to the following transactions: the cash received by the Company in connection with the Company’ s sale and divestment of its non-ophthalmology related compounding revenue line and related intangible assets, and the net gain on sale; the net proceeds from the sale of 2,376,426 shares of the Company’ s common stock, at a price of $10.52 per share, after deducting underwriting discounts and commissions, structuring and commitment fees, and estimated offering expenses payable by the Company; the net proceeds from the sale of $40,250,000 aggregate principal amount of 11.875% senior unsecu..." |
|
| 01/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/11/2022 |
8-K
| Termination of a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 10/05/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"HARROW HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2022 December 31, 2021 ASSETS Cash and cash equivalents $ 46,438,000 $ 42,167,000 All other current assets 18,265,000 18,495,000 Total current assets 64,703,000 60,662,000 All other assets 33,359,000 37,667,000 TOTAL ASSETS $ 98,062,000 $ 98,329,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities $ 12,922,000 $ 9,722,000 Senior April 2026 Notes, net of discount 72,042,000 71,654,000 All other liabilities 7,704,000 6,022,000 TOTAL LIABILITIES 92,668,000 87,398,000 TOTAL STOCKHOLDERS’ EQUITY 5,394,000 10,931,000 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 98,062,000 $ 98,329,000 -MORE- HROW Announces Second Quarter 2022 Financial Results Page 4 August 9, 2022 HARROW HEALTH, INC. UNAUDITED CONDENSED CONSOLIDATED STAT...",
"Second Quarter Core Results" |
|
| 06/13/2022 |
8-K
| Quarterly results |
| 04/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/31/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results Sixth Consecutive Quarter of Record Revenues Highlights for Fourth Quarter 2021:",
"Harrow Health, Inc. Letter to Stockholders March 10, 2022 To the Stockholders of Harrow Health, Inc.: As a result of the remarkable collective effort of the Harrow family of employees and the patronage of our valued customers, it is my privilege to report that the fourth quarter of 2021 was our sixth consecutive quarter of record performance in many key financial and operational metrics, providing a solid conclusion to 2021 and a springboard for 2022 and beyond. Throughout 2021, our team worked diligently to advance our goal of making Harrow a leading U.S. eyecare company. We bolstered our balance sheet, completed several dynamic transactions, successfully filed our first New Drug Application with the U.S. Food and Drug Administration , continued to work on new potentially accretive deals,..." |
|
| 01/10/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/20/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/09/2021 |
8-K
| Quarterly results |
| 11/09/2021 |
8-K
| Other Events Interactive Data |
| 09/02/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Recitals : WHEREAS, Loan Parties have requested that Lender make available to Borrower a term loan in the original principal amount of $13,500,000.00 , on the terms and conditions hereinafter set forth, and for the purposes hereinafter set forth; and WHEREAS, in order to induce Lender to make the Loan to Borrower, Loan Parties have made certain representations to and agreements with Lender; and WHEREAS, Lender, in reliance upon the representations, agreements and inducements of Loan Parties, has agreed to make the Loan upon the terms and conditions hereinafter set forth. Agreement : NOW, THEREFORE, in consideration of the agreement of Lender to make the Loans, the mutual covenants and agreements hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency o...",
"Investor Contact:" |
|
| 08/23/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/18/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/10/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/10/2021 |
8-K
| Quarterly results |
| 07/27/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 07/21/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/17/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
|
|
|